ATG-101 for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
Fox Chase Cancer Center, Philadelphia, PANon-Hodgkin's Lymphoma+2 MoreATG-101 - Drug
All Sexes
What conditions do you have?

Study Summary

This trialstudies a new drug to treat advanced cancers and a type of lymphoma.

Eligible Conditions
  • Non-Hodgkin Lymphoma
  • Advanced Solid Tumors
  • Solid Metastatic Tumor

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 7 Secondary · Reporting Duration: One year after last patient first dose

One year after last patient first dose
DLT (for Dose Escalation Phase only)
Serum concentrations of ATG-101 and derived PK parameters (for Dose Escalation Phase only)
The incidence of ADA and NAb

Trial Safety

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

482 Total Participants · 1 Treatment Group

Primary Treatment: ATG-101 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: ATG-101 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: one year after last patient first dose

Who is running the clinical trial?

Antengene Biologics LimitedLead Sponsor
1 Previous Clinical Trials
156 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many individuals are being included in this medical trial?

"Indeed, the research hosted on indicates that this trial is actively recruiting patients at 4 different sites with a total of 482 participants needed. This study was first posted around December 15th 2021 and most recently edited in November 14th 2022." - Anonymous Online Contributor

Unverified Answer

What is the desired outcome of this clinical evaluation?

"As reported by the trial sponsor, Antengene Biologics Limited, this study's primary outcome will be Dose Limiting Toxicity (DLT) and it is to be measured over a one-year period. Additionally, secondary objectives include Disease Control Rate (DCR), Overall Response Rate(ORR), as well as pharmacokinetic evaluation of ATG-101 serum concentrations." - Anonymous Online Contributor

Unverified Answer

Is the research team actively seeking additional participants?

"Indeed, the data hosted on attests that this experimental treatment is actively recruiting patients. This trial was initially published on December 15th 2021 and has since been updated on November 14th 2022. There are 482 vacancies across 4 separate medical centres." - Anonymous Online Contributor

Unverified Answer

Are there any serious risks associated with the use of ATG-101?

"The safety of ATG-101 is estimated to be a 1 as this trial has only completed the first stage, which limits available evidence on efficacy and safety." - Anonymous Online Contributor

Unverified Answer

In what geographic regions is this scientific inquiry being conducted?

"This research is being conducted at the University of Colorado Hospital in Boulder, Fox Chase Cancer Center located in Philadephia and the esteemed University of California San Francisco. Additionally, there are 4 other locations involved with this study." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.